EGFR and cancer: Several of these genes have been described as important mediators of cancer cell resistance to targeted therapies.61–63,72 Recently, Noronha et al. described increased signaling through the GAS6-AXL signaling axis in drug-tolerant persister cells, which can mediate resistance to RTK inhibitors in EGFR-mutant lung cancer models.73 We showed enrichment of these proteins in MES cell lines and observed upregulation of these genes after ADRN-to-MES transdifferentiation.